Although anakinra, an IL-1R antagonist, combined with corticosteroid and/or tocilizumab could improve clinical and inflammatory indices in steroid-refractory ICANS without or with CRS after CD19 CAR-T therapy, the improvement of neurotoxicity seemed limited (20). The gene discussed is IL1R1; the disease is congenital rubella syndrome.